Yes, people with Medicare Part D who use Restasis may be eligible for a patient assistance program called myAbbVie Assist. This article discusses whether Medicare covers Restasis, Medicare ...
Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful ...
Sight Sciences Inc (NASDAQ:SGHT) released the six-month SAHARA randomized controlled trial comparing interventional eyelid procedures enabled by TearCare Technology to Restasis for dry eye disease.
Why are Americans, both as patients and taxpayers, paying billions of dollars for a drug whose efficacy is so questionable that it's not approved in the European Union, Australia or New Zealand?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results